nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—CYP3A4—breast cancer	0.133	1	CbGaD
Cabergoline—HTR2B—Raloxifene—breast cancer	0.107	0.291	CbGbCtD
Cabergoline—CYP3A4—Exemestane—breast cancer	0.0345	0.0942	CbGbCtD
Cabergoline—CYP3A4—Letrozole—breast cancer	0.0293	0.0801	CbGbCtD
Cabergoline—CYP3A4—Anastrozole—breast cancer	0.0262	0.0714	CbGbCtD
Cabergoline—CYP3A4—Toremifene—breast cancer	0.0239	0.0653	CbGbCtD
Cabergoline—CYP3A4—Fulvestrant—breast cancer	0.0222	0.0607	CbGbCtD
Cabergoline—CYP3A4—Thiotepa—breast cancer	0.0198	0.0541	CbGbCtD
Cabergoline—CYP3A4—Ixabepilone—breast cancer	0.0181	0.0495	CbGbCtD
Cabergoline—CYP3A4—Lapatinib—breast cancer	0.0174	0.0476	CbGbCtD
Cabergoline—CYP3A4—Raloxifene—breast cancer	0.0132	0.0361	CbGbCtD
Cabergoline—CYP3A4—Vinorelbine—breast cancer	0.00968	0.0264	CbGbCtD
Cabergoline—CYP3A4—Tamoxifen—breast cancer	0.00874	0.0238	CbGbCtD
Cabergoline—CYP3A4—Mitoxantrone—breast cancer	0.00852	0.0233	CbGbCtD
Cabergoline—CYP3A4—Paclitaxel—breast cancer	0.0068	0.0186	CbGbCtD
Cabergoline—CYP3A4—Irinotecan—breast cancer	0.00671	0.0183	CbGbCtD
Cabergoline—CYP3A4—Vinblastine—breast cancer	0.00597	0.0163	CbGbCtD
Cabergoline—CYP3A4—Docetaxel—breast cancer	0.00492	0.0134	CbGbCtD
Cabergoline—CYP3A4—Doxorubicin—breast cancer	0.00367	0.01	CbGbCtD
Cabergoline—ADRA1D—epithelium—breast cancer	0.000705	0.0367	CbGeAlD
Cabergoline—DRD5—female reproductive system—breast cancer	0.000653	0.034	CbGeAlD
Cabergoline—DRD5—female gonad—breast cancer	0.000595	0.0309	CbGeAlD
Cabergoline—ADRA2C—nipple—breast cancer	0.000573	0.0298	CbGeAlD
Cabergoline—Pergolide—CYP2D6—breast cancer	0.000559	0.288	CrCbGaD
Cabergoline—DRD5—endocrine gland—breast cancer	0.000553	0.0288	CbGeAlD
Cabergoline—ADRA1D—female reproductive system—breast cancer	0.000524	0.0272	CbGeAlD
Cabergoline—Lisuride—CYP2D6—breast cancer	0.000485	0.25	CrCbGaD
Cabergoline—Pergolide—CYP3A4—breast cancer	0.00048	0.247	CrCbGaD
Cabergoline—HTR2B—skin of body—breast cancer	0.000466	0.0243	CbGeAlD
Cabergoline—ADRA2A—nipple—breast cancer	0.000457	0.0238	CbGeAlD
Cabergoline—ADRA1D—endocrine gland—breast cancer	0.000443	0.0231	CbGeAlD
Cabergoline—HTR2B—endometrium—breast cancer	0.00044	0.0229	CbGeAlD
Cabergoline—HTR7—epithelium—breast cancer	0.00042	0.0218	CbGeAlD
Cabergoline—Lisuride—CYP3A4—breast cancer	0.000416	0.215	CrCbGaD
Cabergoline—ADRB1—adipose tissue—breast cancer	0.000414	0.0215	CbGeAlD
Cabergoline—HTR2B—uterus—breast cancer	0.000405	0.0211	CbGeAlD
Cabergoline—ADRA1A—epithelium—breast cancer	0.000405	0.0211	CbGeAlD
Cabergoline—HTR1B—female reproductive system—breast cancer	0.000405	0.021	CbGeAlD
Cabergoline—HTR2B—adipose tissue—breast cancer	0.000396	0.0206	CbGeAlD
Cabergoline—HTR1D—female reproductive system—breast cancer	0.000392	0.0204	CbGeAlD
Cabergoline—HTR2C—female reproductive system—breast cancer	0.000388	0.0202	CbGeAlD
Cabergoline—ADRB1—female reproductive system—breast cancer	0.000381	0.0198	CbGeAlD
Cabergoline—HTR2B—female reproductive system—breast cancer	0.000364	0.0189	CbGeAlD
Cabergoline—HTR2B—adrenal gland—breast cancer	0.000356	0.0185	CbGeAlD
Cabergoline—ADRA2C—endometrium—breast cancer	0.000346	0.018	CbGeAlD
Cabergoline—HTR1B—endocrine gland—breast cancer	0.000342	0.0178	CbGeAlD
Cabergoline—ADRA1A—adipose tissue—breast cancer	0.000327	0.017	CbGeAlD
Cabergoline—DRD2—pituitary gland—breast cancer	0.000322	0.0168	CbGeAlD
Cabergoline—ADRB1—endocrine gland—breast cancer	0.000322	0.0167	CbGeAlD
Cabergoline—HTR2A—embryo—breast cancer	0.000321	0.0167	CbGeAlD
Cabergoline—ADRA2C—uterus—breast cancer	0.000319	0.0166	CbGeAlD
Cabergoline—HTR1A—adrenal gland—breast cancer	0.000319	0.0166	CbGeAlD
Cabergoline—ADRA2C—pituitary gland—breast cancer	0.000313	0.0163	CbGeAlD
Cabergoline—HTR7—female reproductive system—breast cancer	0.000312	0.0162	CbGeAlD
Cabergoline—ADRA2C—adipose tissue—breast cancer	0.000312	0.0162	CbGeAlD
Cabergoline—HTR7—adrenal gland—breast cancer	0.000304	0.0158	CbGeAlD
Cabergoline—ADRA1A—adrenal gland—breast cancer	0.000294	0.0153	CbGeAlD
Cabergoline—ADRA2C—adrenal gland—breast cancer	0.00028	0.0146	CbGeAlD
Cabergoline—HTR1A—endocrine gland—breast cancer	0.000276	0.0144	CbGeAlD
Cabergoline—ADRA2A—endometrium—breast cancer	0.000276	0.0144	CbGeAlD
Cabergoline—HTR7—endocrine gland—breast cancer	0.000264	0.0137	CbGeAlD
Cabergoline—HTR2A—epithelium—breast cancer	0.000262	0.0136	CbGeAlD
Cabergoline—ADRA2C—female gonad—breast cancer	0.000261	0.0136	CbGeAlD
Cabergoline—ADRA1A—endocrine gland—breast cancer	0.000255	0.0132	CbGeAlD
Cabergoline—ADRA2A—uterus—breast cancer	0.000255	0.0132	CbGeAlD
Cabergoline—ADRA2A—pituitary gland—breast cancer	0.00025	0.013	CbGeAlD
Cabergoline—DRD2—endocrine gland—breast cancer	0.00025	0.013	CbGeAlD
Cabergoline—ADRA2A—adipose tissue—breast cancer	0.000249	0.0129	CbGeAlD
Cabergoline—ADRA2A—female reproductive system—breast cancer	0.000229	0.0119	CbGeAlD
Cabergoline—ADRA2A—adrenal gland—breast cancer	0.000223	0.0116	CbGeAlD
Cabergoline—HTR2B—lymph node—breast cancer	0.000213	0.0111	CbGeAlD
Cabergoline—HTR2A—pituitary gland—breast cancer	0.000213	0.0111	CbGeAlD
Cabergoline—ADRA2A—female gonad—breast cancer	0.000208	0.0108	CbGeAlD
Cabergoline—HTR2A—female reproductive system—breast cancer	0.000195	0.0101	CbGeAlD
Cabergoline—ADRA2A—endocrine gland—breast cancer	0.000194	0.0101	CbGeAlD
Cabergoline—HTR2A—adrenal gland—breast cancer	0.00019	0.00987	CbGeAlD
Cabergoline—CYP3A4—female reproductive system—breast cancer	0.00018	0.00937	CbGeAlD
Cabergoline—ADRA2C—lymph node—breast cancer	0.000168	0.00872	CbGeAlD
Cabergoline—HTR2A—endocrine gland—breast cancer	0.000165	0.00856	CbGeAlD
Cabergoline—CYP3A4—endocrine gland—breast cancer	0.000152	0.00793	CbGeAlD
Cabergoline—ADRA2A—lymph node—breast cancer	0.000134	0.00696	CbGeAlD
Cabergoline—Upper respiratory tract infection—Doxorubicin—breast cancer	9.94e-05	0.000318	CcSEcCtD
Cabergoline—Fatigue—Paclitaxel—breast cancer	9.91e-05	0.000317	CcSEcCtD
Cabergoline—Asthenia—Gemcitabine—breast cancer	9.85e-05	0.000315	CcSEcCtD
Cabergoline—Arthralgia—Capecitabine—breast cancer	9.84e-05	0.000314	CcSEcCtD
Cabergoline—Pain—Paclitaxel—breast cancer	9.83e-05	0.000314	CcSEcCtD
Cabergoline—Constipation—Paclitaxel—breast cancer	9.83e-05	0.000314	CcSEcCtD
Cabergoline—Confusional state—Docetaxel—breast cancer	9.83e-05	0.000314	CcSEcCtD
Cabergoline—Anxiety—Capecitabine—breast cancer	9.81e-05	0.000313	CcSEcCtD
Cabergoline—Oedema—Docetaxel—breast cancer	9.75e-05	0.000311	CcSEcCtD
Cabergoline—Weight increased—Doxorubicin—breast cancer	9.74e-05	0.000311	CcSEcCtD
Cabergoline—Discomfort—Capecitabine—breast cancer	9.73e-05	0.000311	CcSEcCtD
Cabergoline—Epistaxis—Epirubicin—breast cancer	9.72e-05	0.000311	CcSEcCtD
Cabergoline—Pruritus—Gemcitabine—breast cancer	9.72e-05	0.00031	CcSEcCtD
Cabergoline—Nausea—Thiotepa—breast cancer	9.7e-05	0.00031	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—breast cancer	9.68e-05	0.000309	CcSEcCtD
Cabergoline—Diarrhoea—Irinotecan—breast cancer	9.65e-05	0.000308	CcSEcCtD
Cabergoline—Diarrhoea—Mitoxantrone—breast cancer	9.65e-05	0.000308	CcSEcCtD
Cabergoline—Dry mouth—Capecitabine—breast cancer	9.63e-05	0.000308	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—breast cancer	9.59e-05	0.000306	CcSEcCtD
Cabergoline—Shock—Docetaxel—breast cancer	9.59e-05	0.000306	CcSEcCtD
Cabergoline—Pruritus—Fluorouracil—breast cancer	9.55e-05	0.000305	CcSEcCtD
Cabergoline—Visual impairment—Methotrexate—breast cancer	9.53e-05	0.000304	CcSEcCtD
Cabergoline—Confusional state—Capecitabine—breast cancer	9.52e-05	0.000304	CcSEcCtD
Cabergoline—Feeling abnormal—Paclitaxel—breast cancer	9.48e-05	0.000303	CcSEcCtD
Cabergoline—Oedema—Capecitabine—breast cancer	9.44e-05	0.000301	CcSEcCtD
Cabergoline—Gastrointestinal pain—Paclitaxel—breast cancer	9.4e-05	0.0003	CcSEcCtD
Cabergoline—Diarrhoea—Gemcitabine—breast cancer	9.4e-05	0.0003	CcSEcCtD
Cabergoline—Dizziness—Irinotecan—breast cancer	9.32e-05	0.000298	CcSEcCtD
Cabergoline—Anorexia—Docetaxel—breast cancer	9.29e-05	0.000297	CcSEcCtD
Cabergoline—Shock—Capecitabine—breast cancer	9.28e-05	0.000297	CcSEcCtD
Cabergoline—Rhinitis—Epirubicin—breast cancer	9.28e-05	0.000296	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—breast cancer	9.27e-05	0.000296	CcSEcCtD
Cabergoline—Diarrhoea—Fluorouracil—breast cancer	9.24e-05	0.000295	CcSEcCtD
Cabergoline—Cardiac disorder—Methotrexate—breast cancer	9.18e-05	0.000293	CcSEcCtD
Cabergoline—Hyperhidrosis—Capecitabine—breast cancer	9.12e-05	0.000291	CcSEcCtD
Cabergoline—Oedema peripheral—Epirubicin—breast cancer	9.12e-05	0.000291	CcSEcCtD
Cabergoline—Hypotension—Docetaxel—breast cancer	9.11e-05	0.000291	CcSEcCtD
Cabergoline—Abdominal pain—Paclitaxel—breast cancer	9.09e-05	0.00029	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—breast cancer	9e-05	0.000287	CcSEcCtD
Cabergoline—Anorexia—Capecitabine—breast cancer	9e-05	0.000287	CcSEcCtD
Cabergoline—Vomiting—Mitoxantrone—breast cancer	8.97e-05	0.000286	CcSEcCtD
Cabergoline—Vomiting—Irinotecan—breast cancer	8.97e-05	0.000286	CcSEcCtD
Cabergoline—Dizziness—Fluorouracil—breast cancer	8.93e-05	0.000285	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—breast cancer	8.92e-05	0.000285	CcSEcCtD
Cabergoline—Rash—Mitoxantrone—breast cancer	8.89e-05	0.000284	CcSEcCtD
Cabergoline—Rash—Irinotecan—breast cancer	8.89e-05	0.000284	CcSEcCtD
Cabergoline—Dermatitis—Mitoxantrone—breast cancer	8.88e-05	0.000284	CcSEcCtD
Cabergoline—Dermatitis—Irinotecan—breast cancer	8.88e-05	0.000284	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Docetaxel—breast cancer	8.88e-05	0.000284	CcSEcCtD
Cabergoline—Headache—Mitoxantrone—breast cancer	8.83e-05	0.000282	CcSEcCtD
Cabergoline—Headache—Irinotecan—breast cancer	8.83e-05	0.000282	CcSEcCtD
Cabergoline—Hypotension—Capecitabine—breast cancer	8.82e-05	0.000282	CcSEcCtD
Cabergoline—Insomnia—Docetaxel—breast cancer	8.82e-05	0.000282	CcSEcCtD
Cabergoline—Paraesthesia—Docetaxel—breast cancer	8.75e-05	0.00028	CcSEcCtD
Cabergoline—Alopecia—Methotrexate—breast cancer	8.74e-05	0.000279	CcSEcCtD
Cabergoline—Vomiting—Gemcitabine—breast cancer	8.73e-05	0.000279	CcSEcCtD
Cabergoline—Dyspnoea—Docetaxel—breast cancer	8.69e-05	0.000278	CcSEcCtD
Cabergoline—Somnolence—Docetaxel—breast cancer	8.67e-05	0.000277	CcSEcCtD
Cabergoline—Rash—Gemcitabine—breast cancer	8.66e-05	0.000277	CcSEcCtD
Cabergoline—Dermatitis—Gemcitabine—breast cancer	8.65e-05	0.000276	CcSEcCtD
Cabergoline—Headache—Gemcitabine—breast cancer	8.6e-05	0.000275	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Capecitabine—breast cancer	8.6e-05	0.000275	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—breast cancer	8.59e-05	0.000274	CcSEcCtD
Cabergoline—Vomiting—Fluorouracil—breast cancer	8.59e-05	0.000274	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—breast cancer	8.58e-05	0.000274	CcSEcCtD
Cabergoline—Dyspepsia—Docetaxel—breast cancer	8.58e-05	0.000274	CcSEcCtD
Cabergoline—Insomnia—Capecitabine—breast cancer	8.54e-05	0.000273	CcSEcCtD
Cabergoline—Rash—Fluorouracil—breast cancer	8.52e-05	0.000272	CcSEcCtD
Cabergoline—Dermatitis—Fluorouracil—breast cancer	8.51e-05	0.000272	CcSEcCtD
Cabergoline—Paraesthesia—Capecitabine—breast cancer	8.47e-05	0.000271	CcSEcCtD
Cabergoline—Decreased appetite—Docetaxel—breast cancer	8.47e-05	0.000271	CcSEcCtD
Cabergoline—Hypersensitivity—Paclitaxel—breast cancer	8.47e-05	0.000271	CcSEcCtD
Cabergoline—Headache—Fluorouracil—breast cancer	8.46e-05	0.00027	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—breast cancer	8.44e-05	0.000269	CcSEcCtD
Cabergoline—Dyspnoea—Capecitabine—breast cancer	8.41e-05	0.000269	CcSEcCtD
Cabergoline—Fatigue—Docetaxel—breast cancer	8.4e-05	0.000268	CcSEcCtD
Cabergoline—Nausea—Mitoxantrone—breast cancer	8.38e-05	0.000268	CcSEcCtD
Cabergoline—Nausea—Irinotecan—breast cancer	8.38e-05	0.000268	CcSEcCtD
Cabergoline—Pain—Docetaxel—breast cancer	8.34e-05	0.000266	CcSEcCtD
Cabergoline—Constipation—Docetaxel—breast cancer	8.34e-05	0.000266	CcSEcCtD
Cabergoline—Back pain—Methotrexate—breast cancer	8.33e-05	0.000266	CcSEcCtD
Cabergoline—Dyspepsia—Capecitabine—breast cancer	8.31e-05	0.000265	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—breast cancer	8.27e-05	0.000264	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—breast cancer	8.25e-05	0.000264	CcSEcCtD
Cabergoline—Asthenia—Paclitaxel—breast cancer	8.25e-05	0.000264	CcSEcCtD
Cabergoline—Decreased appetite—Capecitabine—breast cancer	8.2e-05	0.000262	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—breast cancer	8.18e-05	0.000261	CcSEcCtD
Cabergoline—Nausea—Gemcitabine—breast cancer	8.16e-05	0.000261	CcSEcCtD
Cabergoline—Fatigue—Capecitabine—breast cancer	8.14e-05	0.00026	CcSEcCtD
Cabergoline—Pruritus—Paclitaxel—breast cancer	8.14e-05	0.00026	CcSEcCtD
Cabergoline—Pain—Capecitabine—breast cancer	8.07e-05	0.000258	CcSEcCtD
Cabergoline—Constipation—Capecitabine—breast cancer	8.07e-05	0.000258	CcSEcCtD
Cabergoline—Feeling abnormal—Docetaxel—breast cancer	8.03e-05	0.000257	CcSEcCtD
Cabergoline—Nausea—Fluorouracil—breast cancer	8.02e-05	0.000256	CcSEcCtD
Cabergoline—Ill-defined disorder—Methotrexate—breast cancer	7.99e-05	0.000255	CcSEcCtD
Cabergoline—Gastrointestinal pain—Docetaxel—breast cancer	7.97e-05	0.000255	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—breast cancer	7.95e-05	0.000254	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—breast cancer	7.94e-05	0.000254	CcSEcCtD
Cabergoline—Tension—Epirubicin—breast cancer	7.91e-05	0.000252	CcSEcCtD
Cabergoline—Diarrhoea—Paclitaxel—breast cancer	7.87e-05	0.000251	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—breast cancer	7.82e-05	0.00025	CcSEcCtD
Cabergoline—Back pain—Epirubicin—breast cancer	7.79e-05	0.000249	CcSEcCtD
Cabergoline—Feeling abnormal—Capecitabine—breast cancer	7.78e-05	0.000248	CcSEcCtD
Cabergoline—Malaise—Methotrexate—breast cancer	7.76e-05	0.000248	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—breast cancer	7.75e-05	0.000247	CcSEcCtD
Cabergoline—Vertigo—Methotrexate—breast cancer	7.73e-05	0.000247	CcSEcCtD
Cabergoline—Gastrointestinal pain—Capecitabine—breast cancer	7.72e-05	0.000246	CcSEcCtD
Cabergoline—Abdominal pain—Docetaxel—breast cancer	7.71e-05	0.000246	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—breast cancer	7.65e-05	0.000244	CcSEcCtD
Cabergoline—Dizziness—Paclitaxel—breast cancer	7.6e-05	0.000243	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—breast cancer	7.57e-05	0.000242	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—breast cancer	7.47e-05	0.000239	CcSEcCtD
Cabergoline—Abdominal pain—Capecitabine—breast cancer	7.46e-05	0.000238	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—breast cancer	7.34e-05	0.000235	CcSEcCtD
Cabergoline—Arthralgia—Methotrexate—breast cancer	7.33e-05	0.000234	CcSEcCtD
Cabergoline—Tension—Doxorubicin—breast cancer	7.31e-05	0.000234	CcSEcCtD
Cabergoline—Vomiting—Paclitaxel—breast cancer	7.31e-05	0.000234	CcSEcCtD
Cabergoline—Malaise—Epirubicin—breast cancer	7.26e-05	0.000232	CcSEcCtD
Cabergoline—Rash—Paclitaxel—breast cancer	7.25e-05	0.000232	CcSEcCtD
Cabergoline—Dermatitis—Paclitaxel—breast cancer	7.24e-05	0.000231	CcSEcCtD
Cabergoline—Discomfort—Methotrexate—breast cancer	7.24e-05	0.000231	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—breast cancer	7.24e-05	0.000231	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—breast cancer	7.24e-05	0.000231	CcSEcCtD
Cabergoline—Syncope—Epirubicin—breast cancer	7.22e-05	0.000231	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—breast cancer	7.21e-05	0.00023	CcSEcCtD
Cabergoline—Headache—Paclitaxel—breast cancer	7.2e-05	0.00023	CcSEcCtD
Cabergoline—Hypersensitivity—Docetaxel—breast cancer	7.18e-05	0.000229	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—breast cancer	7.17e-05	0.000229	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—breast cancer	7.12e-05	0.000227	CcSEcCtD
Cabergoline—Confusional state—Methotrexate—breast cancer	7.08e-05	0.000226	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—breast cancer	7.08e-05	0.000226	CcSEcCtD
Cabergoline—Asthenia—Docetaxel—breast cancer	6.99e-05	0.000223	CcSEcCtD
Cabergoline—Hypertension—Epirubicin—breast cancer	6.96e-05	0.000222	CcSEcCtD
Cabergoline—Hypersensitivity—Capecitabine—breast cancer	6.95e-05	0.000222	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—breast cancer	6.92e-05	0.000221	CcSEcCtD
Cabergoline—Pruritus—Docetaxel—breast cancer	6.9e-05	0.00022	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—breast cancer	6.86e-05	0.000219	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—breast cancer	6.83e-05	0.000218	CcSEcCtD
Cabergoline—Nausea—Paclitaxel—breast cancer	6.83e-05	0.000218	CcSEcCtD
Cabergoline—Hyperhidrosis—Methotrexate—breast cancer	6.79e-05	0.000217	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—breast cancer	6.78e-05	0.000216	CcSEcCtD
Cabergoline—Asthenia—Capecitabine—breast cancer	6.77e-05	0.000216	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—breast cancer	6.72e-05	0.000215	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—breast cancer	6.71e-05	0.000214	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—breast cancer	6.7e-05	0.000214	CcSEcCtD
Cabergoline—Anorexia—Methotrexate—breast cancer	6.7e-05	0.000214	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—breast cancer	6.68e-05	0.000213	CcSEcCtD
Cabergoline—Pruritus—Capecitabine—breast cancer	6.68e-05	0.000213	CcSEcCtD
Cabergoline—Diarrhoea—Docetaxel—breast cancer	6.67e-05	0.000213	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—breast cancer	6.63e-05	0.000212	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—breast cancer	6.59e-05	0.00021	CcSEcCtD
Cabergoline—Oedema—Epirubicin—breast cancer	6.57e-05	0.00021	CcSEcCtD
Cabergoline—Hypotension—Methotrexate—breast cancer	6.56e-05	0.00021	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—breast cancer	6.55e-05	0.000209	CcSEcCtD
Cabergoline—Shock—Epirubicin—breast cancer	6.47e-05	0.000207	CcSEcCtD
Cabergoline—Diarrhoea—Capecitabine—breast cancer	6.46e-05	0.000206	CcSEcCtD
Cabergoline—Dizziness—Docetaxel—breast cancer	6.45e-05	0.000206	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—breast cancer	6.44e-05	0.000206	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Methotrexate—breast cancer	6.4e-05	0.000204	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—breast cancer	6.36e-05	0.000203	CcSEcCtD
Cabergoline—Insomnia—Methotrexate—breast cancer	6.35e-05	0.000203	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—breast cancer	6.35e-05	0.000203	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—breast cancer	6.32e-05	0.000202	CcSEcCtD
Cabergoline—Paraesthesia—Methotrexate—breast cancer	6.31e-05	0.000201	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—breast cancer	6.27e-05	0.0002	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—breast cancer	6.27e-05	0.0002	CcSEcCtD
Cabergoline—Dyspnoea—Methotrexate—breast cancer	6.26e-05	0.0002	CcSEcCtD
Cabergoline—Somnolence—Methotrexate—breast cancer	6.25e-05	0.000199	CcSEcCtD
Cabergoline—Dizziness—Capecitabine—breast cancer	6.24e-05	0.000199	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—breast cancer	6.21e-05	0.000198	CcSEcCtD
Cabergoline—Vomiting—Docetaxel—breast cancer	6.2e-05	0.000198	CcSEcCtD
Cabergoline—Dyspepsia—Methotrexate—breast cancer	6.18e-05	0.000198	CcSEcCtD
Cabergoline—Rash—Docetaxel—breast cancer	6.15e-05	0.000196	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—breast cancer	6.14e-05	0.000196	CcSEcCtD
Cabergoline—Dermatitis—Docetaxel—breast cancer	6.14e-05	0.000196	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—breast cancer	6.13e-05	0.000196	CcSEcCtD
Cabergoline—Decreased appetite—Methotrexate—breast cancer	6.11e-05	0.000195	CcSEcCtD
Cabergoline—Headache—Docetaxel—breast cancer	6.11e-05	0.000195	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—breast cancer	6.08e-05	0.000194	CcSEcCtD
Cabergoline—Fatigue—Methotrexate—breast cancer	6.06e-05	0.000193	CcSEcCtD
Cabergoline—Pain—Methotrexate—breast cancer	6.01e-05	0.000192	CcSEcCtD
Cabergoline—Vomiting—Capecitabine—breast cancer	6e-05	0.000192	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—breast cancer	5.99e-05	0.000191	CcSEcCtD
Cabergoline—Shock—Doxorubicin—breast cancer	5.99e-05	0.000191	CcSEcCtD
Cabergoline—Rash—Capecitabine—breast cancer	5.95e-05	0.00019	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—breast cancer	5.95e-05	0.00019	CcSEcCtD
Cabergoline—Dermatitis—Capecitabine—breast cancer	5.94e-05	0.00019	CcSEcCtD
Cabergoline—Headache—Capecitabine—breast cancer	5.91e-05	0.000189	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—breast cancer	5.9e-05	0.000189	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—breast cancer	5.88e-05	0.000188	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—breast cancer	5.86e-05	0.000187	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—breast cancer	5.84e-05	0.000187	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—breast cancer	5.8e-05	0.000185	CcSEcCtD
Cabergoline—Nausea—Docetaxel—breast cancer	5.79e-05	0.000185	CcSEcCtD
Cabergoline—Feeling abnormal—Methotrexate—breast cancer	5.79e-05	0.000185	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—breast cancer	5.79e-05	0.000185	CcSEcCtD
Cabergoline—Gastrointestinal pain—Methotrexate—breast cancer	5.74e-05	0.000183	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—breast cancer	5.72e-05	0.000183	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—breast cancer	5.68e-05	0.000182	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—breast cancer	5.67e-05	0.000181	CcSEcCtD
Cabergoline—Pain—Epirubicin—breast cancer	5.62e-05	0.00018	CcSEcCtD
Cabergoline—Constipation—Epirubicin—breast cancer	5.62e-05	0.00018	CcSEcCtD
Cabergoline—Nausea—Capecitabine—breast cancer	5.61e-05	0.000179	CcSEcCtD
Cabergoline—Abdominal pain—Methotrexate—breast cancer	5.55e-05	0.000177	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—breast cancer	5.54e-05	0.000177	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—breast cancer	5.5e-05	0.000176	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—breast cancer	5.46e-05	0.000174	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—breast cancer	5.42e-05	0.000173	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—breast cancer	5.42e-05	0.000173	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—breast cancer	5.41e-05	0.000173	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—breast cancer	5.38e-05	0.000172	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—breast cancer	5.35e-05	0.000171	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—breast cancer	5.29e-05	0.000169	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—breast cancer	5.24e-05	0.000168	CcSEcCtD
Cabergoline—Pain—Doxorubicin—breast cancer	5.2e-05	0.000166	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—breast cancer	5.2e-05	0.000166	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—breast cancer	5.2e-05	0.000166	CcSEcCtD
Cabergoline—Hypersensitivity—Methotrexate—breast cancer	5.18e-05	0.000165	CcSEcCtD
Cabergoline—Asthenia—Methotrexate—breast cancer	5.04e-05	0.000161	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—breast cancer	5.01e-05	0.00016	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—breast cancer	4.97e-05	0.000159	CcSEcCtD
Cabergoline—Pruritus—Methotrexate—breast cancer	4.97e-05	0.000159	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—breast cancer	4.84e-05	0.000155	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—breast cancer	4.81e-05	0.000154	CcSEcCtD
Cabergoline—Diarrhoea—Methotrexate—breast cancer	4.81e-05	0.000154	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—breast cancer	4.72e-05	0.000151	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—breast cancer	4.65e-05	0.000149	CcSEcCtD
Cabergoline—Dizziness—Methotrexate—breast cancer	4.65e-05	0.000148	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—breast cancer	4.5e-05	0.000144	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—breast cancer	4.48e-05	0.000143	CcSEcCtD
Cabergoline—Vomiting—Methotrexate—breast cancer	4.47e-05	0.000143	CcSEcCtD
Cabergoline—Rash—Methotrexate—breast cancer	4.43e-05	0.000141	CcSEcCtD
Cabergoline—Dermatitis—Methotrexate—breast cancer	4.43e-05	0.000141	CcSEcCtD
Cabergoline—Headache—Methotrexate—breast cancer	4.4e-05	0.000141	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—breast cancer	4.36e-05	0.000139	CcSEcCtD
Cabergoline—Dizziness—Epirubicin—breast cancer	4.35e-05	0.000139	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—breast cancer	4.3e-05	0.000137	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—breast cancer	4.18e-05	0.000134	CcSEcCtD
Cabergoline—Nausea—Methotrexate—breast cancer	4.17e-05	0.000133	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—breast cancer	4.16e-05	0.000133	CcSEcCtD
Cabergoline—Rash—Epirubicin—breast cancer	4.15e-05	0.000132	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—breast cancer	4.14e-05	0.000132	CcSEcCtD
Cabergoline—Headache—Epirubicin—breast cancer	4.12e-05	0.000132	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—breast cancer	4.02e-05	0.000128	CcSEcCtD
Cabergoline—Nausea—Epirubicin—breast cancer	3.91e-05	0.000125	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—breast cancer	3.87e-05	0.000124	CcSEcCtD
Cabergoline—Rash—Doxorubicin—breast cancer	3.84e-05	0.000123	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—breast cancer	3.83e-05	0.000122	CcSEcCtD
Cabergoline—Headache—Doxorubicin—breast cancer	3.81e-05	0.000122	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—breast cancer	3.61e-05	0.000115	CcSEcCtD
Cabergoline—ADRA2A—Signaling Pathways—ERBB2—breast cancer	2.9e-06	1.74e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—breast cancer	2.89e-06	1.74e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—breast cancer	2.89e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	2.89e-06	1.74e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—breast cancer	2.89e-06	1.74e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—breast cancer	2.88e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—breast cancer	2.87e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—breast cancer	2.87e-06	1.73e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—breast cancer	2.86e-06	1.72e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—breast cancer	2.86e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	2.86e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MTOR—breast cancer	2.86e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	2.86e-06	1.72e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—JUN—breast cancer	2.85e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—breast cancer	2.84e-06	1.71e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CTNNB1—breast cancer	2.83e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—breast cancer	2.83e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—breast cancer	2.83e-06	1.7e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—breast cancer	2.82e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—SRC—breast cancer	2.82e-06	1.7e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—breast cancer	2.82e-06	1.69e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—breast cancer	2.81e-06	1.69e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—breast cancer	2.81e-06	1.69e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—breast cancer	2.81e-06	1.69e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK3—breast cancer	2.81e-06	1.69e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—JUN—breast cancer	2.81e-06	1.69e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—breast cancer	2.81e-06	1.69e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—COMT—breast cancer	2.8e-06	1.68e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—breast cancer	2.8e-06	1.68e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CTNNB1—breast cancer	2.79e-06	1.68e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTP1—breast cancer	2.79e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK3—breast cancer	2.78e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—SRC—breast cancer	2.78e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—breast cancer	2.78e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—breast cancer	2.77e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—breast cancer	2.77e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—breast cancer	2.77e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—breast cancer	2.77e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CDKN1A—breast cancer	2.77e-06	1.66e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—breast cancer	2.76e-06	1.66e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—breast cancer	2.75e-06	1.66e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—breast cancer	2.75e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—JUN—breast cancer	2.75e-06	1.65e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—HMOX1—breast cancer	2.75e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—breast cancer	2.75e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—breast cancer	2.75e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK3—breast cancer	2.75e-06	1.65e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ITPR1—breast cancer	2.74e-06	1.65e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—breast cancer	2.73e-06	1.64e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—breast cancer	2.73e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—breast cancer	2.73e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—breast cancer	2.73e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	2.73e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFB1—breast cancer	2.72e-06	1.64e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1A—breast cancer	2.72e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—breast cancer	2.72e-06	1.64e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—breast cancer	2.71e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—breast cancer	2.71e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—breast cancer	2.7e-06	1.63e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK8—breast cancer	2.7e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFB1—breast cancer	2.7e-06	1.62e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—breast cancer	2.69e-06	1.62e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—breast cancer	2.69e-06	1.62e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK3—breast cancer	2.69e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	2.68e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—breast cancer	2.68e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—breast cancer	2.67e-06	1.61e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK3—breast cancer	2.67e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—breast cancer	2.67e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—breast cancer	2.67e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	2.66e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFB1—breast cancer	2.66e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—breast cancer	2.66e-06	1.6e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK8—breast cancer	2.66e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	2.65e-06	1.6e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—breast cancer	2.65e-06	1.59e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—breast cancer	2.65e-06	1.59e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—breast cancer	2.65e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—breast cancer	2.65e-06	1.59e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—breast cancer	2.64e-06	1.59e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ABCB1—breast cancer	2.64e-06	1.59e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—breast cancer	2.63e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—breast cancer	2.63e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—breast cancer	2.63e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—breast cancer	2.61e-06	1.57e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—breast cancer	2.61e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—breast cancer	2.61e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFB1—breast cancer	2.61e-06	1.57e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK8—breast cancer	2.6e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK3—breast cancer	2.6e-06	1.56e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—breast cancer	2.6e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—breast cancer	2.59e-06	1.56e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFB1—breast cancer	2.59e-06	1.56e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TYMS—breast cancer	2.59e-06	1.56e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—breast cancer	2.58e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—breast cancer	2.58e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—breast cancer	2.57e-06	1.54e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—NCOR1—breast cancer	2.56e-06	1.54e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTM1—breast cancer	2.56e-06	1.54e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.56e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—breast cancer	2.56e-06	1.54e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SRC—breast cancer	2.56e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK3—breast cancer	2.56e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—breast cancer	2.55e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—JUN—breast cancer	2.55e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	2.54e-06	1.53e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—breast cancer	2.54e-06	1.53e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—breast cancer	2.54e-06	1.53e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—breast cancer	2.54e-06	1.53e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	2.53e-06	1.52e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—breast cancer	2.53e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—breast cancer	2.53e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—breast cancer	2.52e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFB1—breast cancer	2.52e-06	1.52e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SRC—breast cancer	2.52e-06	1.51e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—breast cancer	2.5e-06	1.5e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—breast cancer	2.49e-06	1.5e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—breast cancer	2.49e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—breast cancer	2.49e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—breast cancer	2.48e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFB1—breast cancer	2.48e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	2.48e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—breast cancer	2.47e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—breast cancer	2.47e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—breast cancer	2.47e-06	1.48e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—breast cancer	2.47e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SRC—breast cancer	2.47e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—breast cancer	2.46e-06	1.48e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—breast cancer	2.46e-06	1.48e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—breast cancer	2.45e-06	1.48e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GPX1—breast cancer	2.45e-06	1.47e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—breast cancer	2.44e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—breast cancer	2.43e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—breast cancer	2.43e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—breast cancer	2.43e-06	1.46e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CYP1A1—breast cancer	2.43e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—breast cancer	2.42e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK8—breast cancer	2.42e-06	1.45e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—breast cancer	2.41e-06	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—breast cancer	2.41e-06	1.45e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ERCC2—breast cancer	2.41e-06	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—breast cancer	2.4e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—breast cancer	2.4e-06	1.44e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—breast cancer	2.39e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—breast cancer	2.38e-06	1.43e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—breast cancer	2.38e-06	1.43e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK3—breast cancer	2.36e-06	1.42e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—breast cancer	2.35e-06	1.42e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—breast cancer	2.35e-06	1.42e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—breast cancer	2.34e-06	1.41e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—breast cancer	2.34e-06	1.4e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK3—breast cancer	2.32e-06	1.4e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—breast cancer	2.32e-06	1.39e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—breast cancer	2.3e-06	1.38e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	2.3e-06	1.38e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—breast cancer	2.29e-06	1.38e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SRC—breast cancer	2.29e-06	1.38e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFB1—breast cancer	2.29e-06	1.38e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—breast cancer	2.28e-06	1.37e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK3—breast cancer	2.27e-06	1.37e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—breast cancer	2.27e-06	1.36e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—MTHFR—breast cancer	2.26e-06	1.36e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—breast cancer	2.26e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—breast cancer	2.25e-06	1.36e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—breast cancer	2.25e-06	1.36e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFB1—breast cancer	2.25e-06	1.35e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—breast cancer	2.24e-06	1.35e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—breast cancer	2.24e-06	1.35e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—breast cancer	2.23e-06	1.34e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—breast cancer	2.23e-06	1.34e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—breast cancer	2.22e-06	1.34e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—breast cancer	2.22e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—breast cancer	2.21e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—breast cancer	2.21e-06	1.33e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—breast cancer	2.21e-06	1.33e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—breast cancer	2.21e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFB1—breast cancer	2.2e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—breast cancer	2.19e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—breast cancer	2.16e-06	1.3e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	2.15e-06	1.29e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—breast cancer	2.14e-06	1.29e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—breast cancer	2.14e-06	1.29e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—breast cancer	2.13e-06	1.28e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—breast cancer	2.12e-06	1.28e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—breast cancer	2.12e-06	1.27e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	2.11e-06	1.27e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK3—breast cancer	2.11e-06	1.27e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—breast cancer	2.11e-06	1.27e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—breast cancer	2.1e-06	1.26e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—breast cancer	2.1e-06	1.26e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAV1—breast cancer	2.09e-06	1.26e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—breast cancer	2.08e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—breast cancer	2.08e-06	1.25e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—breast cancer	2.08e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—breast cancer	2.08e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—breast cancer	2.08e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—breast cancer	2.05e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—breast cancer	2.05e-06	1.23e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—breast cancer	2.05e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFB1—breast cancer	2.05e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—breast cancer	2.04e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—breast cancer	2.04e-06	1.23e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—breast cancer	2.04e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—breast cancer	2.03e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—breast cancer	2.01e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—breast cancer	2.01e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.98e-06	1.19e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—breast cancer	1.96e-06	1.18e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—breast cancer	1.95e-06	1.18e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—breast cancer	1.95e-06	1.17e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—breast cancer	1.95e-06	1.17e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.92e-06	1.15e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—breast cancer	1.9e-06	1.14e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—breast cancer	1.9e-06	1.14e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.9e-06	1.14e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—breast cancer	1.89e-06	1.14e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—breast cancer	1.88e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.88e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.88e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—breast cancer	1.87e-06	1.12e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—breast cancer	1.85e-06	1.11e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—breast cancer	1.85e-06	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—breast cancer	1.81e-06	1.09e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—breast cancer	1.81e-06	1.09e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—breast cancer	1.8e-06	1.08e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—breast cancer	1.8e-06	1.08e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—breast cancer	1.77e-06	1.07e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—breast cancer	1.75e-06	1.05e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.74e-06	1.05e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.74e-06	1.04e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—breast cancer	1.72e-06	1.04e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—breast cancer	1.72e-06	1.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—breast cancer	1.7e-06	1.02e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—breast cancer	1.7e-06	1.02e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—breast cancer	1.69e-06	1.01e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—breast cancer	1.67e-06	1.01e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—breast cancer	1.66e-06	9.99e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—breast cancer	1.65e-06	9.92e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.61e-06	9.7e-06	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—breast cancer	1.59e-06	9.57e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—NOS3—breast cancer	1.58e-06	9.49e-06	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—breast cancer	1.56e-06	9.41e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—breast cancer	1.54e-06	9.28e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—breast cancer	1.53e-06	9.22e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—breast cancer	1.46e-06	8.76e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—breast cancer	1.44e-06	8.68e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.42e-06	8.56e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—breast cancer	1.26e-06	7.57e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—breast cancer	8.88e-07	5.34e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—breast cancer	7.25e-07	4.36e-06	CbGpPWpGaD
